Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Hepatocyte-specific HDAC3 ablation promotes hepatocellular carcinoma in females by suppressing Foxa1/2

Authors: Yahong Xu, Yongjie Zhu, Zhenru Wu, Shengfu Li, Mingyang Shao, Qing Tao, Qing Xu, Yuwei Chen, Yuke Shu, Menglin Chen, Yongjie Zhou, Yujun Shi

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC), the most common primary liver cancer, prevails mainly in males and has long been attributed to androgens and higher circumstantial levels of interleukin-6 (IL-6) produced by resident hepatic macrophages.

Methods

Constitutively hepatocyte-specific histone deacetylase 3 (HDAC3)-deficient (HDAC3LCKO) mice and constitutively hepatocyte-specific HDAC3 knockout and systemic IL-6 simultaneously ablated (HDAC3LCKO& IL-6−/−) mice were used in our study to explore the causes of sex differences in HCC. Additionally, we performed human HCC tissues with an IHC score. Correlation analysis and linear regression plots were constructed to reveal the association between HDAC3 and its candidate genes. To further elucidate that HDAC3 controls the expression of Foxa1/2, we knocked down HDAC3 in HUH7 liver cancer cells.

Results

We observed a contrary sex disparity, with an earlier onset and higher incidence of HCC in female mice when HDAC3 was selectively ablated in the liver. Loss of HDAC3 led to constant liver injury and the spontaneous development of HCC. Unlike the significant elevation of IL-6 in male mice at a very early age, female mice exhibit stable IL-6 levels, and IL-6 ablation did not eliminate the sex disparity in hepatocarcinogenesis in HDAC3-deficient mice. Oestrogen often protects the liver when combined with oestrogen receptor alpha (ERα); however, ovariectomy in HDAC3-ablated female mice significantly delayed tumourigenesis. The oestrogen-ERα axis can also play a role in tumour promotion in the absence of Foxa1 and Foxa2 in the receptor complex. Loss of HDAC3 profoundly reduced the expression of both Foxa1 and Foxa2 and impaired the binding between Foxa1/2 and ERα. Furthermore, a more frequent HDAC3 decrease accompanied by the simultaneous Foxa1/2 decline was found in female HCC compared to that in male HCC.

Conclusion

In summary, we reported that loss of HDAC3 reduces Foxa1/2 and thus promotes HCC development in females in an oestrogen-dependent manner.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Thomas L, Petrick J, McGlynn K. Liver cancer. In: Thun M, Linet M, Cerhan J, Haiman C, Schottenfeld D, editors. Cancer Epidemiology and Prevention. 4th ed. Oxford University Press; 2018. pp. 635–60. Thomas L, Petrick J, McGlynn K. Liver cancer. In: Thun M, Linet M, Cerhan J, Haiman C, Schottenfeld D, editors. Cancer Epidemiology and Prevention. 4th ed. Oxford University Press; 2018. pp. 635–60.
3.
go back to reference Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in Cancer Mortality and Survival. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1629–37.CrossRefPubMedPubMedCentral Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in Cancer Mortality and Survival. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1629–37.CrossRefPubMedPubMedCentral
4.
go back to reference Dorak M, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet. 2012;28:3:268. Dorak M, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet. 2012;28:3:268.
5.
go back to reference El-Serag H, Rudolph K. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007;132(7):2557–76.CrossRefPubMed El-Serag H, Rudolph K. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007;132(7):2557–76.CrossRefPubMed
7.
go back to reference Kalra M, Mayes J, Assefa S, Kaul A, Kaul R. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol. 2008;14(39):5945–61.CrossRefPubMedPubMedCentral Kalra M, Mayes J, Assefa S, Kaul A, Kaul R. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol. 2008;14(39):5945–61.CrossRefPubMedPubMedCentral
8.
go back to reference Shimizu I, Yasuda M, Mizobuchi Y, Ma YR, Liu F, Shiba M, et al. Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats. Gut. 1998;42(1):112–9.CrossRefPubMedPubMedCentral Shimizu I, Yasuda M, Mizobuchi Y, Ma YR, Liu F, Shiba M, et al. Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats. Gut. 1998;42(1):112–9.CrossRefPubMedPubMedCentral
9.
go back to reference Tsutsui S, Yamamoto R, Iishi H, Tatsuta M, Tsuji M, Terada N. Promoting effect of ovariectomy on hepatocellular tumorigenesis induced in mice by 3’-methyl-4-dimethylaminoazobenzene. Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(6):371–5.CrossRefPubMed Tsutsui S, Yamamoto R, Iishi H, Tatsuta M, Tsuji M, Terada N. Promoting effect of ovariectomy on hepatocellular tumorigenesis induced in mice by 3’-methyl-4-dimethylaminoazobenzene. Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(6):371–5.CrossRefPubMed
10.
go back to reference Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol. 2012;228(2):216–29.CrossRefPubMed Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol. 2012;228(2):216–29.CrossRefPubMed
11.
go back to reference Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008;135(3):947–55.CrossRefPubMed Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008;135(3):947–55.CrossRefPubMed
12.
go back to reference Wu M, Ma W, Hsu C, Chen YL, Ou JH, Ryan CK, et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med. 2010;2(32):32ra35.CrossRefPubMedPubMedCentral Wu M, Ma W, Hsu C, Chen YL, Ou JH, Ryan CK, et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med. 2010;2(32):32ra35.CrossRefPubMedPubMedCentral
13.
go back to reference Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, et al. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 2013;57(2):678–88.CrossRefPubMed Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, et al. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 2013;57(2):678–88.CrossRefPubMed
14.
15.
go back to reference Bhaskara S, Chyla B, Amann J, Knutson SK, Cortez D, Sun ZW, et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell. 2008;30(1):61–72.CrossRefPubMedPubMedCentral Bhaskara S, Chyla B, Amann J, Knutson SK, Cortez D, Sun ZW, et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell. 2008;30(1):61–72.CrossRefPubMedPubMedCentral
16.
go back to reference Ji H, Zhou Y, Zhuang X, Zhu Y, Wu Z, Lu Y, et al. HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition. Cancer Res. 2019;79(14):3676–88.CrossRefPubMedPubMedCentral Ji H, Zhou Y, Zhuang X, Zhu Y, Wu Z, Lu Y, et al. HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition. Cancer Res. 2019;79(14):3676–88.CrossRefPubMedPubMedCentral
17.
go back to reference Naugler W, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121–4.CrossRefPubMed Naugler W, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121–4.CrossRefPubMed
18.
go back to reference Lu XF, Cao XY, Zhu YJ, Wu ZR, Zhuang X, Shao MY, et al. Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway. Cell Death Dis. 2018;9(30):398.CrossRefPubMedPubMedCentral Lu XF, Cao XY, Zhu YJ, Wu ZR, Zhuang X, Shao MY, et al. Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway. Cell Death Dis. 2018;9(30):398.CrossRefPubMedPubMedCentral
19.
go back to reference Jozwik K, Carroll J. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012;12(6):381–5.CrossRefPubMed Jozwik K, Carroll J. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012;12(6):381–5.CrossRefPubMed
20.
go back to reference Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685–9.CrossRefPubMedPubMedCentral Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685–9.CrossRefPubMedPubMedCentral
21.
go back to reference Hurtado A, Holmes K, Ross-Innes C, Schmidt D, Carroll J. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011;43(1):27–33.CrossRefPubMed Hurtado A, Holmes K, Ross-Innes C, Schmidt D, Carroll J. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011;43(1):27–33.CrossRefPubMed
23.
go back to reference Oie S, Matsuzaki K, Yokoyama W, Murayama A, Yanagisawa J. HDAC3 regulates stability of estrogen receptor alpha mRNA. Biochem Biophys Res Commun. 2013;432(2):236–41.CrossRefPubMed Oie S, Matsuzaki K, Yokoyama W, Murayama A, Yanagisawa J. HDAC3 regulates stability of estrogen receptor alpha mRNA. Biochem Biophys Res Commun. 2013;432(2):236–41.CrossRefPubMed
24.
go back to reference Park SH, Kim H, Kwak S, Jeong JH, Lee J, Hwang JT, et al. HDAC3-ERalpha selectively regulates TNF-alpha-Induced apoptotic cell death in MCF-7 human breast Cancer cells via the p53 signaling pathway. Cells. 2020;9(5):1280.CrossRefPubMedPubMedCentral Park SH, Kim H, Kwak S, Jeong JH, Lee J, Hwang JT, et al. HDAC3-ERalpha selectively regulates TNF-alpha-Induced apoptotic cell death in MCF-7 human breast Cancer cells via the p53 signaling pathway. Cells. 2020;9(5):1280.CrossRefPubMedPubMedCentral
25.
go back to reference Zhou Y, Zhang L, Ji H, Lu X, Xia J, Li L, et al. MiR-17 ~ 92 ablation impairs liver regeneration in an estrogen‐dependent manner. J Cell Mol Med. 2016;20(5):939–48.CrossRefPubMedPubMedCentral Zhou Y, Zhang L, Ji H, Lu X, Xia J, Li L, et al. MiR-17 ~ 92 ablation impairs liver regeneration in an estrogen‐dependent manner. J Cell Mol Med. 2016;20(5):939–48.CrossRefPubMedPubMedCentral
26.
go back to reference Bergmann J, Müller M, Baumann N, et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma. Hepatology. 2017;65(1):89–103.CrossRefPubMed Bergmann J, Müller M, Baumann N, et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma. Hepatology. 2017;65(1):89–103.CrossRefPubMed
27.
go back to reference Aleksandrova K, Boeing H, Nöthlings U, Jenab M, Fedirko V, Kaaks R, et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology. 2014;60(3):858–71.CrossRefPubMed Aleksandrova K, Boeing H, Nöthlings U, Jenab M, Fedirko V, Kaaks R, et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology. 2014;60(3):858–71.CrossRefPubMed
28.
go back to reference Yager J, Liehr J. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol. 1996;36:203–32.CrossRefPubMed Yager J, Liehr J. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol. 1996;36:203–32.CrossRefPubMed
29.
go back to reference Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64(6):1403–15.CrossRefPubMed Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64(6):1403–15.CrossRefPubMed
30.
go back to reference Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339–42.CrossRefPubMed Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339–42.CrossRefPubMed
Metadata
Title
Hepatocyte-specific HDAC3 ablation promotes hepatocellular carcinoma in females by suppressing Foxa1/2
Authors
Yahong Xu
Yongjie Zhu
Zhenru Wu
Shengfu Li
Mingyang Shao
Qing Tao
Qing Xu
Yuwei Chen
Yuke Shu
Menglin Chen
Yongjie Zhou
Yujun Shi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11393-1

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine